Latest news in cancer
Efficacy of CAR T Cell Therapy in B-Cell lymphoma Richter Transformation
CAR T cell therapy has shown promising efficacy in treating B-cell lymphoma Richter Transformation, a rare and aggressive disease. This advanced therapy...
Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report
Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This...
What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?
For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR...
CARSgen presents latest data of Satri-cel therapy in ASCO 2024
At ASCO 2024, CARSgen unveiled new data on Satri-cel, their promising CAR-T cell therapy for cancer treatment. The latest findings highlighted significant...
Can CAR T cell therapy shortcomings be avoided by NK Cell therapy?
NK Cell therapy vs CAR T-Cell therapy The FDA’s approval of the first CAR T cell therapy in 2017 was widely celebrated as a significant advancement in...
CAR T Cell therapy for refractory systemic lupus erythematosus in China
CAR T cell therapy has emerged as a promising treatment for refractory systemic lupus erythematosus (SLE) in China. This innovative approach involves...
Zevorcabtagene autoleucel (Zevra-cel therapy) approved for R/R multiple myeloma
SHANGHAI, China, April 30, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the...
After amazing growth of CAR T-Cell therapy: what’s next?
CAR T-cell therapy has rapidly transformed cancer treatment by reprogramming a patient's T-cells to attack cancer cells, demonstrating remarkable success in...
Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS
Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients,...
Nogapendekin alfa inbakicept-pmln is approved by the USFDA for BCG-unresponsive non-muscle invasive bladder cancer
"Nogapendekin Alfa Inbakicept-PMLN, a novel immunotherapy, shows promise in treating bladder cancer when combined with BCG therapy. This innovative approach...
Alectinib has been approved by the USFDA as adjuvant treatment for ALK-positive non-small cell lung cancer
The FDA's recent approval of alectinib marks a significant advancement in the treatment landscape for ALK-positive non-small cell lung cancer (NSCLC). As an...
NMPA approves zevorcabtagene autoleucel CAR T Cell therapy for R/R multiple myeloma
Zevor-Cel therapy Chinese regulators have approved zevorcabtagene autoleucel (zevor-cel; CT053), an autologous CAR T-cell therapy, for the treatment of adult...
Understanding BCMA: A Revolutionary Target in Cancer Treatment
Introduction In the ever-evolving realm of oncological treatment, scientists persistently seek out unconventional targets that can amplify the effectiveness of...
Human-Based CAR T Cell Therapy: Breakthroughs and Challenges
Human-based CAR T-cell therapy revolutionizes cancer treatment by genetically modifying a patient's own immune cells to target and destroy cancer cells. By...
Understanding Cytokine Release Syndrome: Causes, Symptoms, and Treatment
Cytokine Release Syndrome (CRS) is an immune system reaction often triggered by certain treatments like immunotherapy or CAR-T cell therapy. It involves an...
Role of paramedics in the success of CAR T Cell therapy
Paramedics play a crucial role in the success of CAR T-cell therapy by ensuring seamless patient care throughout the treatment process. They provide vital...
How Targeted Therapy is Revolutionizing Advanced Cancer Treatment?
In the field of oncology, the emergence of targeted therapy has revolutionized the treatment landscape for advanced cancers. Unlike conventional chemotherapy,...
Utilizing Immunotherapy to Treat Late-Stage Cancers
Introduction Immunotherapy has become a groundbreaking method in cancer treatment, especially for advanced-stage cancer treatments that have...
Survivorship and long-term care in advanced cancers
Dive into the complexities of survivorship and long-term care for individuals facing advanced cancers. Discover the latest advancements in care coordination...
FasTCAR-T GC012F demonstrated overall 100% response rate in newly diagnosed multiple myeloma
Introduction Even in transplant-eligible (TE) patients, typical first-line treatments for high-risk (HR) newly-diagnosed multiple myeloma (NDMM) have dismal...
CAR T Cell therapy for AIDS related B-Cell malignancies
CAR T cell therapy for HIV-related B cell malignancies involves genetically modifying a patient's T cells to express chimeric antigen receptors (CARs)...
Cancer statistics in India 2024: Incidence, estimates and projections
In 2024, cancer will remain a significant health challenge in India. The country sees over 1.5 million new cases a year. Breast and oral cancers are most...
India declared cancer capital of the world – Apollo report
India declared cancer capital of the world India was designated as the “cancer capital of the world” in the 4th edition of Apollo Hospitals’...
Mirvetuximab soravtansine-gynx is approved by the USFDA for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
March 2024: The Food and Drug Administration has granted approval for mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc. [now a part of AbbVie]) to be...
Ponatinib with chemotherapy has received accelerated approval by the USFDA for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
March 2024: Ponatinib (Iclusig, Takeda Pharmaceuticals U.S.A., Inc.) has received fast approval from the Food and Drug Administration for use in combination...
Zanubrutinib is approved by the USFDA for relapsed or refractory follicular lymphoma
March 2024: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) in combination with obinutuzumab has been granted accelerated approval by the Food and Drug...
Nivolumab in combination with cisplatin and gemcitabine is approved by the USFDA for unresectable or metastatic urothelial carcinoma
March 2024: The Food and Drug Administration has granted approval for the use of nivolumab (Opdivo, Bristol-Myers Squibb Company) in conjunction with cisplatin...
Inotuzumab ozogamicin is approved by the USFDA for pediatric patients with acute lymphoblastic leukemia
6th March 2024: Inotuzumab ozogamicin (Besponsa, Pfizer) has been granted approval by the Food and Drug Administration for the treatment of relapsed or...
Understanding relations between MRD and CAR T-Cell therapy
What is MRD in cancer treatment? Measurable Residual Disease, or MRD, is the name for the very few cancer cells that stay in the body after or during...
Mesenchymal stem cell therapy in neurological disorders
Neurological diseases are big problems around the world because they cause a lot of death and disability. Traditional treatments haven’t always worked,...
Orphan drug designation is given by FDA to CART T-Cell Therapy A2B530 for the treatment of colorectal cancer
In March 2024, a news release said that A2B530 (A2 Biotherapeutics), a CAR T-cell therapy, had been given Orphan Drug Designation to treat colorectal cancer...
Iovance’s Amtagvi is approved by USFDA as first T-cell therapy for a solid tumor
Iovance Biotherapeutics’ first-of-its-kind immunotherapy was approved by the FDA. This means that T-cell therapy, which has changed the way some types of...
Amivantamab-vmjw is approved by the USFDA for EGFR exon 20 insertion-mutated non-small cell lung cancer indications
The Food and Drug Administration approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) in combination with carboplatin and pemetrexed on March 1, 2024....
Osimertinib with chemotherapy is approved by the USFDA for EGFR-mutated non-small cell lung cancer
The Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP) in combination with platinum-based chemotherapy for patients...
Lifileucel is approved by the USFDA for unresectable or metastatic melanoma
The Food and Drug Administration granted accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics, Inc.) on February 16, 2024. This approval is for...
Tepotinib is approved by the USFDA for metastatic non-small cell lung cancer
The Food and Drug Administration officially approved tepotinib (Tepmetko, EMD Serono, Inc.) on February 15, 2024, for adult patients with metastatic non-small...
Need help? Our team is ready to assist you.
We wish a speedy recovery of your dear and near one.